Loading…
Rigel Pharmaceuticals, Inc. is projected to rise to $63.79 by 2027, a +47% move from its current price of $43.30. RIGL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $42.24 | $43.31 | $44.40 | +0.03% |
| Jul 13 | $41.82 | $43.32 | $44.87 | +0.06% |
| Jul 14 | $41.51 | $43.33 | $45.24 | +0.09% |
| Jul 15 | $41.24 | $43.34 | $45.55 | +0.11% |
| Jul 16 | $41.01 | $43.36 | $45.83 | +0.14% |
| Jul 17 | $40.81 | $43.37 | $46.09 | +0.17% |
| Jul 18 | $40.62 | $43.38 | $46.33 | +0.20% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $40.62 | $43.38 | $46.33 | +0.20% |
| Week 2 | $39.61 | $43.47 | $47.71 | +0.40% |
| Week 3 | $38.87 | $43.56 | $48.81 | +0.60% |
| Week 4 | $38.26 | $43.64 | $49.78 | +0.80% |
| Week 5 | $37.75 | $43.73 | $50.66 | +1.01% |
| Week 6 | $37.30 | $43.82 | $51.48 | +1.21% |
| Week 7 | $36.89 | $43.91 | $52.25 | +1.41% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Rigel Pharmaceuticals, Inc. is a biotechnology company that develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory AML with a susceptible IDH1 mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic RET fusion-positive NSCLC, as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.
It also develops R289, an oral IRAK1/4 inhibitor, being advanced to Phase 1b for hematology-oncology, autoimmune, and inflammatory diseases. Rigel has strategic collaborations with MD Anderson Cancer Center for olutasidenib in AML and other IDH1-mutant hematologic cancers, and with CONNECT to evaluate olutasidenib with temozolomide in high-grade glioma with IDH1 mutation. Rigel was incorporated in 1996 and is headquartered in South San Francisco, California.
Rigel Pharmaceuticals, Inc. (RIGL) is currently priced at $42.56 per share and has a market capitalization of $787.45M. The stock is ranked 2728 by market cap. The near-term price outlook is informed by a forecast that shows an upward price path from 2026 to 2050, with the 2026 average price matching the current price at $42.56 and rising to a 2050 average of $878.55 and a max of $1,598.86.
The forecast also provides a series of yearly ROIs, culminating in a 2050 ROI of 1964.3% and a strong bullish trajectory after 2026.
A major floor 42.7% below — a decisive break under it would weaken the trend.
The nearest floor, 31.0% below — buyers have tended to step in here.
Price is pressing into resistance (1.1% away) — a breakout level to watch.
A major ceiling 21.5% above — clearing it would confirm fresh momentum.
Key RIGL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RIGL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $42.41 | Buy | $42.17 | Buy |
| MA 10 | $40.59 | Buy | $40.62 | Buy |
| MA 20 | $37.39 | Buy | $38.09 | Buy |
| MA 50 | $32.52 | Buy | $34.49 | Buy |
| MA 100 | $31.25 | Buy | $33.27 | Buy |
| MA 200 | $34.21 | Buy | $32.22 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 75.60 | Sell |
| Stoch RSI (14) | 33.04 | Neutral |
| CCI (20) | 107.49 | Buy |
| Williams %R (14) | -14.85 | Info |
| MACD (12,26,9) | 0.50 | Buy |
| ROC (12) | 19.49 | Buy |
| Bollinger %B (20,2) | 0.85 | Neutral |
| Stochastic %K (14) | 85.15 | Sell |
| TRIX (15) | 1.14 | Buy |
| Awesome (5,34) | 8.08 | Buy |
| Ultimate (7,14,28) | 76.97 | Sell |
| Momentum (10) | 5.56 | Buy |
| Aroon Osc (25) | 88.00 | Buy |
| Hull MA (9) | 44.20 | Sell |
| ADX (14) | 42.58 | Buy |
| ATR (14) | 0.86 | Info |
In the near term, the sentiment is bullish as indicated by the overall technical read. RSI14 is 80, with the stock trading above both the SMA50 of $31.76 and the SMA200 of $34.09, suggesting a positive trend. The defined support level sits at $29.01 and the resistance at $42.56, framing a near-term outlook.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $25.44 | $43.30 | $57.07 | 0% | Neutral | |
| $51.20 | $63.79 | $83.80 | +47% | Bullish | |
| $64.28 | $82.11 | $111.62 | +90% | Bullish | |
| $76.90 | $100.31 | $140.05 | +132% | Bullish | |
| $89.26 | $118.58 | $169.33 | +174% | Bullish | |
| $94.95 | $128.26 | $186.80 | +196% | Bullish | |
| $110.71 | $151.88 | $225.14 | +251% | Bullish | |
| $124.91 | $173.85 | $261.89 | +302% | Bullish | |
| $147.84 | $208.61 | $318.93 | +382% | Bullish | |
| $187.85 | $268.58 | $416.28 | +520% | Bullish | |
| $277.16 | $420.49 | $690.43 | +871% | Bullish | |
| $554.18 | $930.11 | $1,661.81 | +20.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $25.44 | $43.30 | $51.03 | +0.00% |
| August 2026 | $37.07 | $43.65 | $52.72 | +0.83% |
| September 2026 | $37.50 | $44.44 | $54.21 | +1.80% |
| October 2026 | $36.56 | $43.56 | $53.60 | -1.97% |
| November 2026 | $36.41 | $43.59 | $54.01 | +0.05% |
| December 2026 | $38.06 | $45.75 | $57.07 | +4.97% |
Click any year to see its month-by-month RIGL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Rigel Pharmaceuticals, Inc.'s 2026 outlook centres on $43.30, within a $25.44 to $57.07 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, RIGL could reach as high as $83.80, with a base case around $63.79 and support toward $51.20 — roughly +47% from $43.30. Momentum favours further upside here.
Expect RIGL to range from $64.28 to $111.62 through 2028. The $82.11 average target implies a +90% move from current prices. That is up +29% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The RIGL price prediction for 2029 points to an average of $100.31 (low $76.90, high $140.05) — a potential gain of +132% on today's $43.30. Momentum favours further upside here.
In 2030, RIGL is projected to trade between $89.26 and $169.33, averaging $118.58 — a potential gain of +174% from today's $43.30. That is up +18% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Rigel Pharmaceuticals, Inc.'s 2031 outlook centres on $128.26, within a $94.95 to $186.80 range. That is up +8% on the projected 2030 average. That marks a +196% change versus current levels. Momentum favours further upside here.
By 2032, RIGL could reach as high as $225.14, with a base case around $151.88 and support toward $110.71 — roughly +251% from $43.30. Buyers look set to stay in control over this stretch.
Expect RIGL to range from $124.91 to $261.89 through 2033. The $173.85 average target implies a +302% move from current prices. That is up +14% on the projected 2032 average. Momentum favours further upside here.
The RIGL price prediction for 2034 points to an average of $208.61 (low $147.84, high $318.93) — a potential gain of +382% on today's $43.30. Buyers look set to stay in control over this stretch.
In 2035, RIGL is projected to trade between $187.85 and $416.28, averaging $268.58 — a potential gain of +520% from today's $43.30. That is up +29% on the projected 2034 average. Momentum favours further upside here.
Rigel Pharmaceuticals, Inc.'s 2040 outlook centres on $420.49, within a $277.16 to $690.43 range. That is up +57% on the projected 2035 average. That marks a +871% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, RIGL could reach as high as $1,661.81, with a base case around $930.11 and support toward $554.18 — roughly +20.5x from $43.30. Momentum favours further upside here.
Investing $1,000 in RIGL today (≈ 23.097355 RIGL) could be worth
$21,483.02
+$20,483.02 (+2048%) by 2050 · US Dollar
Based on the average projected RIGL price of $930.11 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RIGLwould be worth at today's price.
$1,000 invested in RIGL on Jul 10, 2025 (≈ 51.020407 RIGL) would be worth
$2,208.93
+$1,208.93 (+120.9%) today · 2.21× · US Dollar
Based on a RIGL entry price of $19.6 vs. today's $43.3.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $38.72 | $1,118.16 | +11.8% |
| 1 month ago | $30.91 | $1,400.68 | +40.1% |
| 3 months ago | $29.2 | $1,482.71 | +48.3% |
| 6 months ago | $39.96 | $1,083.46 | +8.3% |
| 1 year ago | $19.6 | $2,208.93 | +120.9% |
| All time (5.0y) ago | $42.1 | $1,028.38 | +2.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RIGL forecast.
Our base-case forecast reaches $87.00 around 2029.
Implied market cap at $87.00: $1.61B
The multi-year forecast outlines a rising price path with sustained bullish sentiment from 2027 onward. The 2026 forecast shows a neutral stance with min $25.44, avg $42.56, max $56.29 and ROI of 0%. By 2027 the avg price rises to $62.37 (min $49.83, max $82.48) with a 46.5% ROI and a bullish sentiment.
The path continues higher with 2030 avg $115.03 and a 170.3% ROI, 2040 avg $399.57 and an 838.8% ROI, and 2050 avg $878.55 with a 1964.3% ROI, all carrying bullish sentiment. The forecast offers substantial upside but remains an estimate and not a guarantee. The largest projected price milestones are in 2030, 2040, and 2050, with ranges widening toward $165.93, $666.31, and $1,598.86 respectively.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $115.03, with a min of $85.87 and a max of $165.93, and an ROI of 170.3%. The sentiment is BULLISH.
The forecast shows bullish sentiment from 2027 onward with rising average prices and positive ROIs (e.g., 46.5% in 2027, 89% in 2028, up to 1964.3% in 2050). However, these are estimates and not guarantees.
The 30-day range is $35.82 to $50.57. The 2026 forecast max is $56.29, indicating the near term could approach or exceed $50 based on the range and forecast.
RSI14 is 80, indicating strong momentum. The SMA50 is $31.76 and the SMA200 is $34.09. The stock has a defined support of $29.01 and a resistance of $42.56; the 30-day range runs from $35.82 to $50.57; annualized volatility is 50%.
2030 avg $115.03 with ROI 170.3%; 2040 avg $399.57 with ROI 838.8%; 2050 avg $878.55 with ROI 1964.3%. All years show bullish sentiment, reflecting a long-term upside but these are estimates, not guarantees.
Rigel Pharmaceuticals, Inc. Community Discussion
0Share your Rigel Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.